In lapatinib-treated patients , the overall risk for National Cancer Institute-Common Terminology Criteria for Adverse Events grade 3 ALT elevation ( > 5 upper limit of normal ) was 2.1 % ; HLA allele carriers had an increased risk of 7.7 % ; in noncarriers , risk was reduced to 0.5 % , comparable to ALT elevation for all patients receiving placebo .